Interferon alfa (a) is the subtype most commonly used and is the most well-studied for treating CTCL. Similar to insulin in administration, interferon-a is injected subcutaneously. Patients ...

SNGX READ THE FULL SNGX RESEARCH REPORT Business Update Phase 3 CTCL Trial to Initiate Before End of 2024 Soligenix, Inc.

The following is a summary of “Integrative epidemiology and immuno-transcriptomics uncover a risk and potential mechanism for ...

The FDA approved denileukin diftitox (Lymphir), the first novel targeted systemic therapy approved for relapsed/refractory (r ...

The US regulator has cleared Lymphir (denileukin diftitox) for the treatment of relapsed or refractory cutaneous T-cell lymphoma (CTCL) after at least one prior systemic therapy, resurrecting the ...

Investigators found that denileukin diftitox, which targets the interleukin-2 receptor, achieves objective response rates in 44% of patients with cutaneous T-cell lymphoma, with a median duration ...

Australians with osteoporosis, a type of skin lymphoma, spinal muscular atrophy and type 2 diabetes will have access to new and expanded medicines ...

German biotech 4SC has filed its oral HDAC inhibitor Kinselby with the EMA, hoping to provide a much-needed new therapy for patients with the rare cancer cutaneous T-Cell lymphoma (CTCL).

Phototherapy involves the use of ultraviolet light for the treatment of skin disease and many dermatologists have phototherapy units in their offices. With these units, ultraviolet light of ...